Disruptions from China’s strict Covid control measures this year have hurt not only consumer-facing companies, but also the country’s growing field of contract research outsourcing (CRO) companies that provide R&D, testing and manufacturing services to drug makers. But don’t tell that to Joinn Laboratories (China) Co. Ltd. (6127.HK; 603127.SH), a leader in the field, which has maintained strong growth so far this year in defiance of market expectations.
作者莫莉，本文僅代表個人觀點
您已閱讀5%（471字），剩餘95%（8193字）包含更多重要資訊，訂閱以繼續探索完整內容，並享受更多專屬服務。